{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:03:19Z","timestamp":1771275799965,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radiotherapy is a cornerstone in the management of node-positive prostate cancer. Advances in imaging modalities and radiation therapy techniques have led to the evolution of treatment standards for this patient population. This review aims to explore the therapeutic advancements of the past decade, with a focus on the role of ultra-hypofractionated radiotherapy in node-positive prostate cancer.<\/jats:p>","DOI":"10.1038\/s41391-025-00976-7","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T15:54:49Z","timestamp":1746719689000},"page":"90-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultra-hypofractionation for node-positive prostate cancer: pushing boundaries and redefining standards"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4873","authenticated-orcid":false,"given":"Jennifer","family":"Le Gu\u00e9velou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Jeandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Angrisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2654-1281","authenticated-orcid":false,"given":"Davide Giovanni","family":"Bosetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6477-6655","authenticated-orcid":false,"given":"Mohamed","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"976_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1002\/cncr.21947","volume":"106","author":"GP Swanson","year":"2006","unstructured":"Swanson GP, Thompson IM, Basler J. Treatment options in lymph node-positive prostate cancer. Cancer. 2006;106:2531\u20139.","journal-title":"Cancer"},{"key":"976_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clgc.2017.08.004","volume":"16","author":"DH Moon","year":"2018","unstructured":"Moon DH, Basak RS, Chen RC. Patterns of care of node-positive prostate cancer patients across the United States: a national cancer data base analysis. Clin Genitourin Cancer. 2018;16:35\u201341.e1.","journal-title":"Clin Genitourin Cancer"},{"key":"976_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","volume":"2","author":"ND James","year":"2016","unstructured":"James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial. JAMA Oncol. 2016;2:348\u201357.","journal-title":"JAMA Oncol"},{"key":"976_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet Lond Engl. 2022;399:447\u201360.","journal-title":"Lancet Lond Engl"},{"key":"976_CR5","first-page":"02254","volume":"S0302-2838","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part i: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;S0302-2838:02254\u20131.","journal-title":"Eur Urol"},{"key":"976_CR6","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V 3.2022."},{"key":"976_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.radonc.2019.05.016","volume":"140","author":"H Lieng","year":"2019","unstructured":"Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, et al. Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol J Eur Soc Ther Radio Oncol. 2019;140:68\u201375.","journal-title":"Radiother Oncol J Eur Soc Ther Radio Oncol"},{"key":"976_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet Lond Engl. 2020;395:1208\u201316.","journal-title":"Lancet Lond Engl"},{"key":"976_CR9","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.1002\/cam4.2985","volume":"9","author":"K Tsuchida","year":"2020","unstructured":"Tsuchida K, Inaba K, Kashihara T, Murakami N, Okuma K, Takahashi K, et al. Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer. Cancer Med. 2020;9:6629\u201337.","journal-title":"Cancer Med"},{"key":"976_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.radonc.2013.08.006","volume":"109","author":"V Fonteyne","year":"2013","unstructured":"Fonteyne V, Lumen N, Ost P, Van Praet C, Vandecasteele K, De Gersem Ir W, et al. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome. Radiother Oncol J Eur Soc Ther Radio Oncol. 2013;109:229\u201334.","journal-title":"Radiother Oncol J Eur Soc Ther Radio Oncol"},{"key":"976_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.adro.2018.12.001","volume":"4","author":"A Pinitpatcharalert","year":"2019","unstructured":"Pinitpatcharalert A, Happersett L, Kollmeier M, McBride S, Gorovets D, Tyagi N, et al. Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer. Adv Radiat Oncol. 2019;4:337\u201344.","journal-title":"Adv Radiat Oncol"},{"key":"976_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clon.2018.03.004","volume":"30","author":"V Murthy","year":"2018","unstructured":"Murthy V, Gupta M, Mulye G, Maulik S, Munshi M, Krishnatry R, et al. Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high-risk and node-positive prostate cancer. Clin Oncol. 2018;30:442\u20137.","journal-title":"Clin Oncol"},{"key":"976_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6558","author":"AU Kishan","year":"2023","unstructured":"Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, et al. Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial. JAMA Oncol. 2023. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6558.","journal-title":"JAMA Oncol"},{"key":"976_CR14","first-page":"02688","volume":"S0302-2838","author":"AU Kishan","year":"2024","unstructured":"Kishan AU, Lamb JM, Wilhalme H, Casado M, Chong N, Zello L, et al. Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial. Eur Urol. 2024;S0302-2838:02688\u20135.","journal-title":"Eur Urol"},{"key":"976_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.clon.2020.10.019","volume":"33","author":"T Telkhade","year":"2021","unstructured":"Telkhade T, Murthy V, Kanala TS, Mathew JM, Phurailatpam R, Mokal S, et al. Safety and efficacy of ultra-hypofractionation in node-positive prostate cancer. Clin Oncol. 2021;33:172\u201380.","journal-title":"Clin Oncol"},{"key":"976_CR16","first-page":"JCO1801097","volume":"36","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol J Am Soc Clin Oncol. 2018;36:JCO1801097.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"976_CR17","first-page":"03773","volume":"S0360-3016","author":"V Murthy","year":"2025","unstructured":"Murthy V, Mallick I, Maitre P, Mulye G, Arunsingh M, Valle L, et al. Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium. Int J Radiat Oncol Biol Phys. 2025;S0360-3016:03773\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"976_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ijrobp.2023.09.053","volume":"118","author":"O Mohamad","year":"2024","unstructured":"Mohamad O, Zamboglou C, Zilli T, Murthy V, Aebersold DM, Loblaw A, et al. Safety of ultrahypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2024;118:998\u20131010.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"976_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07490-0","volume":"20","author":"LC Mendez","year":"2020","unstructured":"Mendez LC, Arifin AJ, Bauman GS, Velker VM, Ahmad B, Lock M, et al. Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial. BMC Cancer. 2020;20:978.","journal-title":"BMC Cancer"},{"key":"976_CR20","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","volume":"92","author":"G Bauman","year":"2015","unstructured":"Bauman G, Ferguson M, Lock M, Chen J, Ahmad B, Venkatesan VM, et al. A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer. Int J Radiat Oncol. 2015;92:856\u201362.","journal-title":"Int J Radiat Oncol"},{"key":"976_CR21","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","volume":"102","author":"HB Musunuru","year":"2018","unstructured":"Musunuru HB, D\u2019Alimonte L, Davidson M, Ho L, Cheung P, Vesprini D, et al. Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): early toxicity and quality of life. Int J Radiat Oncol. 2018;102:1438\u201347.","journal-title":"Int J Radiat Oncol"},{"key":"976_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijrobp.2018.11.011","volume":"104","author":"Y Alayed","year":"2019","unstructured":"Alayed Y, Cheung P, Vesprini D, Liu S, Chu W, Chung H, et al. SABR in high-risk prostate cancer: outcomes from 2 prospective clinical trials with and without elective nodal irradiation. Int J Radiat Oncol. 2019;104:36\u201341.","journal-title":"Int J Radiat Oncol"},{"key":"976_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","volume":"103","author":"D Dearnaley","year":"2019","unstructured":"Dearnaley D, Griffin CL, Lewis R, Mayles P, Mayles H, Naismith OF, et al. Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL). Int J Radiat Oncol. 2019;103:605\u201317.","journal-title":"Int J Radiat Oncol"},{"key":"976_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","volume":"145","author":"V Murthy","year":"2020","unstructured":"Murthy V, Maitre P, Bhatia J, Kannan S, Krishnatry R, Prakash G, et al. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial. Radiother Oncol. 2020;145:71\u201380.","journal-title":"Radiother Oncol"},{"key":"976_CR25","doi-asserted-by":"publisher","first-page":"S2485","DOI":"10.1016\/S0167-8140(24)02299-0","volume":"194","author":"P Ost","year":"2024","unstructured":"Ost P, Siva S, Braband S, Dirix P, Liefhooghe N, Otte F-X, et al. Salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM). Radiother Oncol. 2024;194:S2485\u2013S2487.","journal-title":"Radiother Oncol"},{"key":"976_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","volume":"109","author":"WA Hall","year":"2021","unstructured":"Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, et al. NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer. Int J Radiat Oncol. 2021;109:174\u201385.","journal-title":"Int J Radiat Oncol"},{"key":"976_CR27","first-page":"07680","volume":"S0360-3016","author":"O De Hertogh","year":"2023","unstructured":"De Hertogh O, Le Bihan G, Zilli T, Palumbo S, Jolicoeur M, Crehange G, et al. Consensus delineation guidelines for pelvic lymph node radiation therapy of prostate cancer: on behalf of the Francophone Group of Urological Radiation Therapy (GFRU). Int J Radiat Oncol Biol Phys. 2023;S0360-3016:07680\u20130.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"976_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.eururo.2016.07.043","volume":"71","author":"DE Spratt","year":"2017","unstructured":"Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, et al. Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage. Eur Urol. 2017;71:37\u201343.","journal-title":"Eur Urol"},{"key":"976_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ijrobp.2022.07.011","volume":"114","author":"P Chopade","year":"2022","unstructured":"Chopade P, Maitre P, David S, Panigrahi G, Singh P, Phurailatpam R, et al. Common iliac node-positive prostate cancer treated with curative radiation therapy: N1 or M1a?. Int J Radiat Oncol Biol Phys. 2022;114:711\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00976-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00976-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00976-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:05:46Z","timestamp":1771272346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00976-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00976-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}